# Tirzepatide Dosage: The Clinical Trial and Label Evidence — Tirzepatide Chemical

> Tirzepatide dosage as documented in the FDA label and the SURPASS/SURMOUNT clinical trials: the 2.5-to-15 mg titration ladder, once-weekly subcutaneous injection, half-life, and dose-escalation protocol.

## The short version

Tirzepatide dosage in the FDA label and clinical trials is always once-weekly by subcutaneous injection (under the skin, usually the abdomen, thigh, or upper arm). It starts low — 2.5 mg per week — and steps up every four weeks. The top dose used in the biggest trials was 15 mg per week, which is also the maximum approved dose. The step-up schedule exists because higher doses produce more nausea and other GI side effects, and a slow ramp gives the body time to adjust. The five-day half-life means one missed injection will not immediately undo the steady state, but restarting after a gap may require re-titration. This page covers the label and trial dosing context — not a personal dosing recommendation.

## Tirzepatide dosage: the label and trial titration schedule

The tirzepatide dosage schedule established in the SURPASS and SURMOUNT programmes and reflected in the FDA-approved label is as follows [19]:

- **Starting dose**: 2.5 mg once weekly (4 weeks)
- **Escalation**: increase by 2.5 mg every 4 weeks
- **Maintenance doses studied**: 5 mg, 10 mg, and 15 mg once weekly (the three doses in the SURPASS and SURMOUNT phase 3 trials)
- **Maximum approved dose**: 15 mg once weekly
- **Full escalation to 15 mg**: approximately 20 weeks (five steps)

This titration schedule — used in SURMOUNT-1 [4] and the SURPASS programme [3] — is designed to minimise gastrointestinal adverse effects (primarily nausea, vomiting, diarrhoea, and constipation) that are most frequent during dose escalation. The starting dose of 2.5 mg is below the dose shown to produce glycaemic or weight effect — it is a tolerability ramp, not an efficacy dose [7].

In trial practice, participants who could not tolerate a dose escalation remained at the previous tolerated dose. SURMOUNT-5 used the "maximum tolerated dose" paradigm, allowing participants to stay at 10 mg if 15 mg was not tolerated [5].

## Tirzepatide dose: pharmacokinetic context

The pharmacokinetic profile of tirzepatide (characterised in Urva et al., Diabetes Obes Metab, 2020) supports once-weekly dosing [1, 2]:

- **Half-life**: approximately 5 days
- **Time to steady state**: approximately 4 weeks (approximately four to five half-lives)
- **Route**: subcutaneous injection only (all clinical trials and approved formulations)
- **Binding**: high albumin affinity, conferred by the C20 eicosanedioic-acid fatty-diacid arm via glutamic acid linker + two AEEA units to a lysine side chain

The five-day half-life is the longest in the approved incretin class and is what enables once-weekly administration [1]. Full elimination after stopping takes approximately 25-35 days (five to seven half-lives).

## Tirzepatide injection: route and formulation context

Tirzepatide is administered by subcutaneous injection — the only route used in all clinical trials and the only approved route. The FDA label and clinical-trial protocols specify rotating injection sites between the abdomen, thigh, and upper arm on a weekly schedule [19].

The approved formulation is a subcutaneous solution. Marketed formulations are refrigerated; specific reconstitution and storage parameters are formulation-dependent and outside the scope of the published efficacy literature [7]. The clinical-trial SURMOUNT and SURPASS programmes used a dedicated single-dose injection pen.

Gastrointestinal tolerability is tightly linked to dose escalation speed: the label and trial protocols build in a slow ramp specifically because nausea, vomiting, diarrhoea, and constipation are dose-dependent effects that are most prominent during each dose step and attenuate with continued exposure [17, 19].

## Tirzepatide dose in extended and special-population trials

Beyond the main SURPASS and SURMOUNT programmes, dose and administration context from additional trials:

- **Obstructive sleep apnea** (SURMOUNT-OSA, Malhotra et al., 2024): doses up to 15 mg once weekly; the trial produced the data supporting the OSA FDA indication [15]
- **Heart failure with preserved ejection fraction** (SUMMIT, Packer et al., 2025): doses up to 15 mg once weekly [16]
- **MASH with liver fibrosis** (SYNERGY-MASH, Loomba et al., 2024): doses up to 15 mg once weekly [12]
- **Older adults with type 2 diabetes without obesity** (Rasouli et al., 2025): the pooled SURPASS analysis confirmed consistent glycaemic efficacy, with hypoglycaemia incidence staying low across ages [33]
- **Chinese adults with early type 2 diabetes** (SURPASS-CN-MONO, Yin et al., 2026): 5, 10, and 15 mg once weekly; HbA1c reductions of -2.04, -1.93, -2.02 percentage points versus placebo [35]

Note: compounded tirzepatide versions proliferated during a documented shortage period. Regulators have raised concerns about the quality, purity, and identity of non-FDA-approved compounded formulations — a concern documented in the controversy literature and distinct from the approved product dosed in the trials above.

---

The chemistry and trial record of a dual-receptor agonist, read independently — no clinic, no product, no prescription.